Discovery and characterization of highly potent and selective covalent inhibitors of SARS-CoV-2 PLpro
J. Wu, T. Vaid, H. Kim, J. Lu, R. Demissie, H. Lee, L. W.- M. Fung, J. Chen, C. Xi, Z. Yang, Y. Huang, Z. Zhang, J. Zhang, F. Yan, M. E. Johnson, M. Li
This study identifies and characterizes two covalent PLpro inhibitors, HUP0109 and DX-027, as potential treatments for SARS-CoV-2.
bioRxiv · May 2, 2023 · PreprintPharmacology & Toxicology